Arena Pharmaceuticals

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arena Pharmaceuticals (ARNA) Upgraded to Buy: Here's Why

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock?

Why Is Arena Pharmaceuticals (ARNA) Up 9.1% Since Last Earnings Report?

All You Need to Know About Arena Pharmaceuticals (ARNA) Rating Upgrade to Buy

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q1 2019 Results - Earnings Call Transcript

Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.

Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up

Shares of Arena Pharmaceuticals Inc. declined in Wednesday's extended session after the drug company posted quarterly results that fell short of expectations.

Arena Pharmaceutical shares slide after drug maker reports disappointing financial results

Alnylam Pharmaceuticals

Intuitive Surgical

Medical stocks continued a two-day plunge Thursday on worries over a Bernie Sanders proposal for a single-payer health care system called "Medicare for All."

Medical Stocks Blistered On Sanders Proposal — Is This A Correction?

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Arena Pharmaceuticals (ARNA) Down 10.1% Since Last Earnings Report?

News for Arena Pharmaceuticals Stock (ARNA)